XML 51 R50.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
12 Months Ended
Dec. 31, 2019
USD ($)
Dec. 31, 2019
CNY (¥)
Dec. 31, 2018
USD ($)
Dec. 31, 2018
CNY (¥)
Dec. 31, 2017
USD ($)
segment
Dec. 31, 2017
CNY (¥)
segment
Dec. 31, 2015
USD ($)
Dec. 31, 2015
CNY (¥)
Dec. 31, 2012
USD ($)
Dec. 31, 2012
CNY (¥)
Significant Accounting Policies [Line Items]                    
Research and development expenses $ 11,734,590   $ 9,524,412   $ 6,503,712          
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity 1,173,008   1,192,320              
Impairment loss of equity method investment recognized $ 0   0   0          
Defined Contribution Plan Minimum Annual Contributions Per Employee Percent 25.00% 25.00%                
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent 43.00% 43.00%                
Defined Contribution Plan, Employer Discretionary Contribution Amount $ 5,941,209   5,581,682   $ 3,763,276          
Number of Operating Segments | segment         1 1        
Operating Lease, Right-of-Use Asset 5,566,093                  
Operating lease liability 5,544,576                  
Prepaid Expenses and Other Current Assets [Member]                    
Significant Accounting Policies [Line Items]                    
Deferred Tax Assets, Net, Noncurrent $ 10,430,019   $ 9,107,844              
Xian Huitian Blood Products [Member]                    
Significant Accounting Policies [Line Items]                    
Equity method investment percentage 35.00%   35.00%              
Guizhou Taibang [Member]                    
Significant Accounting Policies [Line Items]                    
Grants received                 $ 2,989,215 ¥ 18,350,000
Grants amortized amount $ 266,217   $ 277,801   $ 271,754          
Shandong Taibang [Member]                    
Significant Accounting Policies [Line Items]                    
Grants received             $ 2,452,864 ¥ 15,000,000    
Grants amortized amount 217,616   227,085   222,143          
Research and Development Expense [Member]                    
Significant Accounting Policies [Line Items]                    
Grants received $ 1,225,147 ¥ 8,468,100 $ 704,795 ¥ 4,837,300 $ 368,093 ¥ 2,405,210        
Minimum [Member]                    
Significant Accounting Policies [Line Items]                    
Equity method investment percentage 20.00%                  
Contractual period of rights 40 years 40 years                
Maximum [Member]                    
Significant Accounting Policies [Line Items]                    
Equity method investment percentage 50.00%                  
Contractual period of rights 50 years 50 years